Iovance Biotherapeutics (IOVA) Receivables - Net (2023 - 2026)
Iovance Biotherapeutics (IOVA) posted quarterly Receivables - Net of $81.8 million for Q1 2026, up 15.25% year-over-year from $70.9 million in Q1 2025, and down 0.84% quarter-over-quarter from $82.4 million in Q4 2025.
Iovance Biotherapeutics (IOVA) Receivables - Net (2023 - 2026) Analysis & Trends
Iovance Biotherapeutics (IOVA) has reported Receivables - Net for 4 consecutive years, with $81.8 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Receivables - Net rose 15.25% year-over-year to $81.8 million; the TTM figure through Mar 2026 stood at $81.8 million (up 15.25% YoY), while the FY2025 annual figure was $82.4 million, up 18.9% from the prior year.
- Receivables - Net fell to $81.8 million in Q1 2026 per IOVA's latest filing, from $82.4 million in the prior quarter.
- Across five years, Receivables - Net topped out at $82.4 million in Q4 2025 and bottomed at $33000.0 in Q2 2023.
- Historically, Receivables - Net has averaged $47.2 million across 4 years, with a median of $59.9 million in 2025.
- Annual changes were most pronounced in 2024 — Receivables - Net jumped 95669.7% — and 2026, when it climbed 15.25%.
- Iovance Biotherapeutics' Receivables - Net stood at $151000.0 in 2023, then jumped by 45820.53% to $69.3 million in 2024, then grew by 18.9% to $82.4 million in 2025, then slipped by 0.84% to $81.8 million in 2026.
- Business Quant data shows IOVA's Receivables - Net at $81.8 million in Q1 2026, $82.4 million in Q4 2025, and $66.8 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Iovance Biotherapeutics | 3.16 Bn | 2.86 Bn | 55.72 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 102.12 Mn |
| Jun 30, 2026 | 102.12 Mn |
| Mar 31, 2026 | 81.76 Mn |
| Mar 31, 2026 | 81.76 Mn |
| Dec 31, 2025 | 82.45 Mn |
| Dec 31, 2025 | 82.45 Mn |
| Sep 30, 2025 | 66.76 Mn |
| Sep 30, 2025 | 66.76 Mn |
| Jun 30, 2025 | 59.94 Mn |
| Jun 30, 2025 | 59.94 Mn |
| Mar 31, 2025 | 70.94 Mn |
| Mar 31, 2025 | 70.94 Mn |
| Dec 31, 2024 | 69.34 Mn |
| Dec 31, 2024 | 69.34 Mn |
| Sep 30, 2024 | 55.77 Mn |
| Sep 30, 2024 | 55.77 Mn |
| Jun 30, 2024 | 31.60 Mn |
| Jun 30, 2024 | 31.60 Mn |
| Mar 31, 2024 | 234,000.00 |
| Mar 31, 2024 | 234,000.00 |